Singer Capital Markets is delighted to have acted as Nominated Adviser and Sole Broker on Renalytix’s (RENX.LN) admission to AIM in October 2018. The Singers team secured cornerstone investors, facilitating a larger free float and walking up valuation between the middle and top of the range. The fundraise was significantly oversubscribed, despite a deteriorating / challenging market, raising £22 million on admission. The IPO was followed by a secondary Placing in July 2019 raising £14 million.

The IPO won the prestigious ‘Transaction of the Year’ Award at the AIM Awards Dinner in 2019.

Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. Having incubated out of another one of Singer Capital Markets’ clients, EKF Diagnostics Holdings plc, Renalytix built KidneyIntelX as a platform solution that uses predictive blood-based biomarkers and can analyse continuously further anonymised information from electronic health records, and other genomic data, and integrate with the care management pathways of healthcare systems such as partner and investor, Mount Sinai.